MedPath

Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

Phase 3
Terminated
Conditions
Depressive Disorder, Major
Interventions
Registration Number
NCT03668600
Lead Sponsor
Naurex, Inc, an affiliate of Allergan plc
Brief Summary

Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
230
Inclusion Criteria
  • Completion of lead-in study
  • Adequate therapeutic benefit in the lead-in study to justify continuation of treatment with rapastinel in the judgement of the investigator
Exclusion Criteria
  • Suicide risk, as determined by meeting any of the following criteria:

    1. A suicide attempt within the past year
    2. Significant risk, as judged by the investigator, based on the psychiatric interview or information collected in the Columbia- Suicide Severity Rating Scale (C-SSRS) at any visit in the lead-in study
    3. Montgomery-Asberg Depression Rating Scale (MADRS) Item 10 score ≥ 5 at any visit during participation in the lead-in study where MADRS was conducted.
  • At imminent risk of injuring self or others or causing significant damage to property, as judged by the investigator

  • Females who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during participation

  • Females of childbearing potential and male partners of females of childbearing potential, not using a reliable means of contraception

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
RapastinelRapastinelRapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
Primary Outcome Measures
NameTimeMethod
Count of Participants Experiencing One or More Treatment Emergent Adverse Events (TEAEs)Up to 45 Weeks

A Treatment Emergent Adverse Event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. An Adverse Drug Reaction was a harmful and unintended reaction that is incurred during routine administration or use of the drug, whose causal relationship with the drug cannot be excluded.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (73)

CITrials

🇺🇸

Riverside, California, United States

Institute for Advanced Medical Research

🇺🇸

Atlanta, Georgia, United States

The Ohio State University Department of Psychiatry

🇺🇸

Columbus, Ohio, United States

Lehigh Center for Clinical Research

🇺🇸

Allentown, Pennsylvania, United States

Patient Priority Clinical Sites

🇺🇸

Cincinnati, Ohio, United States

Earle Research

🇺🇸

Houston, Texas, United States

Clinical Trials of Texas

🇺🇸

San Antonio, Texas, United States

Summit Research Network LLC

🇺🇸

Portland, Oregon, United States

NoesisPharma

🇺🇸

Phoenix, Arizona, United States

Sooner Clinical Research, Inc

🇺🇸

Oklahoma City, Oklahoma, United States

Paradigm Research Professionals

🇺🇸

Oklahoma City, Oklahoma, United States

ProScience Research Group

🇺🇸

Culver City, California, United States

Louisiana Clinical Research

🇺🇸

Shreveport, Louisiana, United States

California Pharmaceutical Research Institute, Inc

🇺🇸

Anaheim, California, United States

Reliable Clinical Research

🇺🇸

Hialeah, Florida, United States

Harmonex Neuroscience Research

🇺🇸

Dothan, Alabama, United States

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Northwest Behavioral Research Center

🇺🇸

Marietta, Georgia, United States

Medical Research Group of Central Florida

🇺🇸

Orange City, Florida, United States

Pharmacology Research Institute

🇺🇸

Los Alamitos, California, United States

Behavioral Research Specialists, LLC

🇺🇸

Glendale, California, United States

Gulfcoast Clinical Research Center

🇺🇸

Fort Myers, Florida, United States

Innovative Clinical Research, Inc

🇺🇸

Lauderhill, Florida, United States

Attalla Consultants, LLC

🇺🇸

Smyrna, Georgia, United States

Comprehensive Psychiatric Care

🇺🇸

Norwich, Connecticut, United States

Meridien Research

🇺🇸

Lakeland, Florida, United States

ActivMed Practices & Research, Inc.

🇺🇸

Methuen, Massachusetts, United States

Bio Behavioral Health

🇺🇸

Toms River, New Jersey, United States

University of Massachusetts Medical School

🇺🇸

Worcester, Massachusetts, United States

Psychiatric Care and Research Center

🇺🇸

O'Fallon, Missouri, United States

Healthy Perspectives - Innovative Mental Health Services. PLLC

🇺🇸

Nashua, New Hampshire, United States

Sun Valley Research Center

🇺🇸

Imperial, California, United States

Synergy Clinical Research Center of Escondido

🇺🇸

Lemon Grove, California, United States

Irvine Center for Clinical Research, Inc

🇺🇸

Irvine, California, United States

California Neuroscience Research

🇺🇸

Sherman Oaks, California, United States

Woodland Research Northwest

🇺🇸

Rogers, Arkansas, United States

Woodland International Research Group

🇺🇸

Little Rock, Arkansas, United States

Pacific Clinical Research Medical

🇺🇸

Upland, California, United States

Viking Clinical Research

🇺🇸

Temecula, California, United States

AMR - Baber Research, Inc.

🇺🇸

Naperville, Illinois, United States

Alexian Brothers Center for Psychiatric Research

🇺🇸

Hoffman Estates, Illinois, United States

Lake Charles Clinical Trials

🇺🇸

Lake Charles, Louisiana, United States

University of Kansas School of Medicine Clinical Trial Unit

🇺🇸

Wichita, Kansas, United States

Coastal Research Associates

🇺🇸

South Weymouth, Massachusetts, United States

Precise Research Centers

🇺🇸

Flowood, Mississippi, United States

St. Charles Psychiatric Associates

🇺🇸

Saint Charles, Missouri, United States

Premier Psychiatric Research Institute, LLC

🇺🇸

Lincoln, Nebraska, United States

SPRI Clinical Trials, LLC

🇺🇸

Brooklyn, New York, United States

Richmond Behavioral Associates

🇺🇸

Staten Island, New York, United States

Manhattan Behavioral Medicine

🇺🇸

New York, New York, United States

Midwest Clinical Research Center LLC

🇺🇸

Dayton, Ohio, United States

Professional Psychiatric Services

🇺🇸

Mason, Ohio, United States

Coastal Carolina Research Center

🇺🇸

Mount Pleasant, South Carolina, United States

Research Strategies of Memphis, LLC

🇺🇸

Memphis, Tennessee, United States

Houston Clinical Trials

🇺🇸

Bellaire, Texas, United States

Red Oak Psychiatry Associates, PA

🇺🇸

Houston, Texas, United States

North Texas Clinical Trials

🇺🇸

Fort Worth, Texas, United States

Grayline Clinical Drug Trials

🇺🇸

Wichita Falls, Texas, United States

iResearch Atlanta, LLC

🇺🇸

Decatur, Georgia, United States

ATP Clinical Research Inc.

🇺🇸

Costa Mesa, California, United States

Research Centers of America

🇺🇸

Oakland Park, Florida, United States

Southern California Research LLC.

🇺🇸

Beverly Hills, California, United States

Psychiatric and Behavioral Solutions

🇺🇸

Salt Lake City, Utah, United States

Psychiatric Alliance of the Blue Ridge, Inc

🇺🇸

Charlottesville, Virginia, United States

Red River Medical Research Center, LLC

🇺🇸

Oklahoma City, Oklahoma, United States

Donald J. Garcia, Jr., MD, PA

🇺🇸

Austin, Texas, United States

David A. Medina, MD

🇺🇸

Orlando, Florida, United States

Carolina Clinical Trials, Inc.

🇺🇸

Charleston, South Carolina, United States

Community Clinical Research

🇺🇸

Austin, Texas, United States

Albuquerque Neuroscience, Inc

🇺🇸

Albuquerque, New Mexico, United States

Finger Lakes Clinical Research

🇺🇸

Rochester, New York, United States

Capstone Clinical Research

🇺🇸

Libertyville, Illinois, United States

Dr. Cherian Verghese

🇺🇸

Norristown, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath